Related Experiment Video
Updated: Mar 6, 2026

Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
Case report: apixaban-induced thrombocytopenia
1Intensive Care Unit Hornsby Hospital Hornsby New South Wales Australia.
Abstract:
Apixaban is a relatively new drug, and its safety profile is still being established. Thrombocytopenia is an uncommon, but life-threatening side effect with no previous published case repots. Clinicians must be aware of this and exercise caution particularly as some studies hint that it may be used in the management of HIT.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

